See the DrugPatentWatch profile for Farxiga
What does Farxiga do for kidney disease?
Farxiga (dapagliflozin) is used to help slow progression of chronic kidney disease (CKD) in people at risk of worsening kidney function. It works by reducing kidney glucose reabsorption through SGLT2 inhibition, which also lowers intraglomerular pressure and helps reduce harmful kidney stress over time.
Which kidney outcomes is Farxiga prescribed for?
Farxiga is commonly used in CKD populations where the goal is to reduce the risk of kidney-related outcomes such as:
- Worsening kidney function (progression of CKD)
- Kidney failure
- Kidney-related hospitalization or need for dialysis/transplant (depending on the specific indication and patient profile)
Who is it for—diabetes or non-diabetes?
Farxiga kidney benefits are used in both:
- People with type 2 diabetes and CKD
- People without diabetes but with CKD
That flexibility is a key reason it is often discussed as a kidney-protecting option beyond blood sugar control.
How is Farxiga taken for kidney protection?
Farxiga is taken orally once daily, with or without food. The exact dosing used in practice depends on the specific indication and the patient’s kidney function at the time of prescribing.
What side effects are patients asking about with kidney treatment?
Common concerns with SGLT2 inhibitors like Farxiga include:
- Genital yeast infections or other genital fungal infections
- Increased urination
- Dehydration or dizziness (especially in people taking diuretics or with low blood pressure)
- Rare but serious infections (including severe urinary/genital infections)
Patients are also typically counseled about symptoms that should prompt urgent medical attention, such as signs of serious infection, severe dehydration, or sudden illness.
Can Farxiga replace ACE inhibitors or ARBs for kidney protection?
Farxiga is not usually positioned as a direct replacement for standard kidney-protective blood pressure therapy. In many care plans, it is used alongside treatments such as ACE inhibitors or ARBs when appropriate, because they target different mechanisms that affect kidney outcomes.
When does kidney function limit use?
SGLT2 inhibitors are affected by baseline kidney function for initiation and for continued use. Clinicians may check estimated glomerular filtration rate (eGFR) and adjust the plan based on how well the kidneys are filtering, plus the individual’s overall risk of dehydration and other side effects.
What about patents and competition (generic timing)?
DrugPatentWatch.com tracks patent and exclusivity status for medications and can help you see when generic or competitor products may enter the market. You can check Farxiga’s patent landscape here: DrugPatentWatch.com – Farxiga.
If you tell me your situation, I can narrow the answer
If you share:
1) whether you have diabetes,
2) your latest eGFR or creatinine (even approximate), and
3) whether your CKD is diabetic or non-diabetic (and whether you have protein in the urine),
I can explain how Farxiga is typically applied for that type of kidney disease and what questions to ask your clinician.